Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2018

View Archived Issues

Novo Nordisk licenses EPGN-696 from Epigen

CEPI and IAVI partner to develop Lassa fever vaccine

Recombinant human pentraxin 2 slows decline in lung function in IPF patients

Updated results strengthen previously reported 2-year survival rate of TG-01

Recro receives complete response letter from the FDA for intravenous meloxicam

Celon Pharma evaluates 5-HT6 receptor antagonist PZ-KKN-94 in vitro and in vivo

Portola Pharmaceuticals receives milestone payment following Andexxa approval

Phase III iLLUMINATE trial of Imbruvica plus Gazyva in first-line CLL/SLL meets primary endpoint

PACIFIC trial of Imfinzi in NSCLC meets second primary endpoint of overall survival

Alliance between Bicycle Therapeutics and ThromboGenics sees milestone and expansion

FDA grants fast track designation for KB-103

New prostate cancer model generated through Pmepa1 gene knockout

FDA approves Palynziq for adults with phenylketonuria

First patient dosed in first-in-human trial of MCLA-158 in solid tumors

Preliminary results from phase I pivotal study of Tonmya

Chugai seeks Japanese approval for Actemra for adult-onset Still's disease

New NTRK1 inhibitors discovered at Shionogi

Phase III study of Arzerra plus bendamustine in indolent NHL did not meet primary endpoint

FDA accepts NDA resubmission for Dsuvia

Takeda describes metabotropic glutamate mGlu7 receptor agonists

Vanderbilt University discovers muscarinic acetylcholine M4 receptor positive allosteric modulators

CLCF1 biomarker may help diagnose delayed graft function in kidney transplantation

European designation decisions for BioCryst's BCX-7353 for HAE

Sichuan Kelun-Biotech Biopharmaceutical presents antiviral compounds

Ficolin binding inhibitors patented by Osaka University

License agreement and collaborations support development of human Nipah virus vaccine

Voyager Therapeutics develops AAV gene therapy for Friedreich's ataxia

Researchers create a renal medullary carcinoma mouse model for chemotherapy testing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...